[Non-English content] [Non-English content] [Non-English content] [Non-English content] I will actually change to English because there is an international interest for our presentations. I hope the discussion after the presentation is going to be in Swedish so everyone can use the language that they are comfortable with. Hamlet BioPharma has released an end of year report and a quarterly report for the fourth quarter. It is a very special day for us today. We have been in this situation many times, but this report is very special because it marks the moment, the time when we have been able to reach significant goals. Goals that we have had an eye on for a long time since we started developing the company, and which are now in our pocket or very near. The company overview that you also can see from the document that you are downloading from us is that Hamlet BioPharma translates innovation to clinical success. We develop innovative treatments targeting malignant tumors and antibiotic resistant infections. We built a robust pipeline in collaboration with Linnane Pharma and Lund University, which is crucial for these successes. We also have built a network that helps us access international networks of specialists and also offer a basis for reaching the market through partnerships and commercialization opportunities. Today, the situation with our clinical assets can be summarized as you see here. This is a richer image than you are used to seeing. You are used to seeing the bladder cancer in blue, where we are initiating phase III. We are also adding a new indication, which is carcinoma in situ, and we can go back and discuss that in more detail if you like. This is a collaboration with the U.S. Center. For the infection project, our recurrent urinary tract infection studies and bladder pain studies have ended phase II, and we are adding a new, more severe infection indication to understand more about antibiotic resistance and about the potency of our treatment for severe infections. Because it is a special day today, maybe we should go back just quickly to where it all started with Hamlet. Once upon a time, we were looking for novel antibiotics in mother's milk. Some of you remember this story. Some of you have even been investors since the very start. We were looking for antibiotics, and we had bacteria and lung cancer cells in the test tube. Adding something from breast milk that turned out to be Hamlet, we saw that the cells died and the bacteria disappeared. The early chemistry, which took quite a while, showed that Hamlet was a complex between a milk protein, alpha-lactalbumin, and fatty acid, oleic acid. The name Hamlet means human alpha-lactalbumin made lethal to tumor cells. Some years later, we were able to identify Alpha1H, which of course, is the investigative new drug. That is what the IND application with the FDA is covering. It means that we can use Alpha1H safely for different clinical trials, clinical indications under this IND that we have received. The molecule is the N-terminal domain of the milk protein. It reproduces the effects of Hamlet. We have synthetically manufactured it on a large scale. I think you have seen that from our recent press releases and at phase III quality, which is very important. Our patents have been extended to various interesting mechanisms, and there is protection, therapeutic effects, first in animal models and more recently in patients with bladder cancer. Many people ask us about the mechanism of action of Alpha1H, and I think I can summarize it here based on data that comes from both animals and patients. These are real mechanisms that we see when we treat tumors in vivo. The molecule is taken up by the tumors very efficiently. That can be a problem for other drugs, but for Alpha1, there is an affinity for the tumor. Tumor cell shedding, which means that the cells detach from the tumor, and in case of bladder cancer, they are peed out by the patient and the tumor gets smaller and smaller. Apoptosis like cell death. This is a nice form of cell death that many of the tumor cells undergo, and they respond to Alpha1H. This is why we have so few side effects in treatment studies of this drug. Inhibition of oncogene-driven tumor environment. When you talk to the FDA, there is still an emphasis on clinical endpoint surgery, the traditional way of evaluating clinical effects. We are adding to that the ability to also see the molecular response of the tumor in great detail. We are hoping in the future that this will also become a variable that can be used for continued clinical trials. We have activation of a broad protective immune response. Similar to BCG, one of the main current treatments of bladder cancer. This small peptide with an oleic acid attached to it is a very versatile molecule with a rich effect in the treated patients. Just one image from Arunima in the group who is doing special imaging technologies. This shows you a nucleus of a tumor cell. The blue edge here is the edge of a nucleus. The green is Alpha1, and the pink is Alpha1-OA. This is a picture of a nucleus in a tumor cell that has taken up Alpha1H, and that is on its way to die. What we also see in the patients is a very quick response. This is two hours gene expression data, which means that we look at everything in the tumor that is affected and in the cells that come out of the patient. Even after two hours, all the blue dots here and the blue parts of this figure here show that there is inhibition. What used to be the high cancer gene expression, the high metabolism, the high activity of a living, growing tumor can get inhibited, and it can be inhibited by Alpha1 very quickly. You also know from previous presentations that there are effects on the tumor after the end of treatment, which is about six treatments. We have a number of images like this where we can show before and after, and where we can also measure the tumor. Treatment in our latest study resulted in a complete or partial response in 82% of the tumors. With a lower dose, we had 45% responders. I talked about the gene expression effect, the fact that we can suppress the cancer gene expression. That was in cells after two hours. This is now in pieces of tumor that were obtained from the patients after the end of treatment, so about one month later. You see the same thing. You see all the blue dots, which means that all of these cancer genes now are not expressed to the same extent. They are inhibited. In the middle panel, you see that this is cancer neoplasia that has to do with metastasis, for example, invasion, advanced malignant tumors. All these hallmarks of a tumor are inhibited, significantly inhibited after treatment. This also includes bladder cancer genes, where in the diagram to the right, you see the blue dots. Blue means inhibited. The red ones are the ones that are still active. Finally, the fourth criterion of effect, which is the immune response. Beautifully shown urine swabs from the patients taken over the treatment period, and where you see all these immune response molecules that potentially have anti-tumor effects. We compared them here, Shahram in the lab compared them to what is known about BCG treatment. You can see the huge overlap. Alpha1H is triggering an immune response in the patients that is similar to the drug of choice, BCG. Now to explaining a little bit more about our ongoing plans and the future plans. Where does Alpha1 fit in as a treatment for bladder cancer? Where we start is newly diagnosed patients with non-muscle invasive bladder cancer, it is this abbreviation. So far, nothing is done between the time of diagnosis and the TURBT, which is an abbreviation for surgery. The first surgery is done in the bladder and the tumor is removed. We propose at this time while the patient is waiting for surgery is an excellent time to introduce Alpha1H neoadjuvant therapy. It is called neoadjuvant because it is intended to help the surgery, either by making the tumor smaller or making the tumor go away, reducing the need for surgery. The burden of the TURBT for the patient varies, but it is a significant factor in the evaluation of bladder cancer therapy and future ways of treating bladder cancer therapy. After surgery, the main goal is to reduce the risk for recurrences, of course. The current treatments are mitomycin and BCG. There are also other treatments, but these are two of the main treatments that are used. What we propose is to also use Alpha1H as an adjuvant now, either alone or together with these treatments that are already in place. The new option that I talked about where we will collaborate with the U.S. University of Iowa is to treat patients with carcinoma in situ. It is a different type of tumor where the tumor grows in the wall of the bladder. Because it grows in the wall, it is difficult to remove by surgery. Often these patients would have to undergo what is called cystectomy, which means removal of the bladder. We are very interested in seeing if Alpha1, which actually acts on the wall of the bladder and removes tumor cells into the urine, if that will have effects. This is why we are initiating this study. Alpha1 also has an interesting pipeline in terms of other types of cancers. You may remember that we have tested other members of the HAMLET family as well for colon cancer, skin tumors and brain tumors. We are always aware of this pipeline that we would like to explore with given more substantial funding to cover all these indications. Now back to the second part, the infection part, the green arrows here, where, as I said, we have completed phase II for recurrent urinary tract infection and bladder pain syndrome, and are in the planning stages for more severe infectious trials. Our concept is to treat bacterial infections without antibiotics. It does not mean that we are not honoring the enormous importance of antibiotics. In most cases, antibiotics are still efficient, but we are all aware of the need for novel alternatives, especially in patients with resistant organisms. The model here is to the left that the bacteria create disease. All the red stuff is either kidney infection or bladder infection. Kidney infection is one of the most important causes of sepsis worldwide, and urosepsis is one of the big killers. These are important infections, not just for the local effects on the patient, but also because they can become much more severe. We have developed four treatments that are not acting as antibiotics. They do not directly kill the bacteria, they act on the disease response. These treatments are IRF7 siRNA. IRF7 is a transcription factor that regulates the disease, but you have to quiet it down, otherwise it will drive severe disease. We have been able to do that in our animal models. NlpD is a protein from nice bacteria that the bacteria use to shut off the immune response in the host so they can just sit there and feed themselves and feel good. That protein we have developed, Ines and me in the group especially, into a recombinant protein that can be used therapeutically. This is one of the press releases that we have had in the last quarter, a publication in The Journal of Infectious Diseases. Lon is a new molecule that is able to suppress one of the biggest oncogenes, one of the most well-established oncogenes, which is called MYC. An oncogene means it is related to cancer, but we have shown that it is also a driver of severe infections. If we treat the animals with recombinant Lon, they are protected. This is the third, and the fourth is the one that you already know, IL-1RA, the IL-1 receptor antagonist anakinra that has proven efficacious already in clinical trials. The treatment effects are inhibition of excessive innate immune responses, inhibition of inflammation and disease, and accelerated bacteria clear. Despite the fact that they do not act as antibiotics, they can enable the immune system of the patient to go back and get rid of the bacteria, which I think is fantastic. On the right, you see a graph showing that treatment of infections caused by antibiotic resistance traits is actually working. The red line is animals treated without anything. You see the bacteria counts. The black line is antibiotics because these bacteria do not respond to the antibiotics used. The green line is treatment with three of our drug candidates that actually are able to both clear the disease and infection. We are very excited about this part of the company's work. Just a brief comment on the clinical phase II data where we compared the treatment with IL-1RA to antibiotics. Some of you have seen this before, but the outcome of a phase II study showed reduced symptoms, recurrence rates, increased quality of life, and inhibition of immune activation for both antibiotics and our drug to the same extent, which is a first-in-class success story actually in infectious disease. Of course, advantages of immunotherapy is that you can provide alternatives, you can reduce the selective pressure on resistance, and the effects on the normal flora and other side effects in the treated individual. Just a short comment on tuberculosis, which is a project driven by Professor Godaly in collaboration with Hamlet BioPharma. There is very interesting data showing that the peptide used by Professor Godaly is actually breaking down the bacteria. You can see the breakdown of the mycobacteria here compared to control. We have also signed a collaboration agreement with a biotech company in Korea, ImmunoForge, to develop novel delivery technology for use in patients with tuberculosis. Treatment of chronic pain, an unexpected effect of the cystitis work, where we have also completed a clinical study showing proof of concept that the patients get better, their pain is reduced, and they are also maintained on this treatment for long periods of time, which means that they can go back to work, they can sleep, all of these advantages. This is a huge untapped market. I will show you this very quickly. Just robust pipeline, 180 patents or patent families. We are getting new patent candidates approved quickly, and the British firm helping us with this are excellent. These are the citations that we have in the end-of-year report from Jakob and me. Right? Yeah. Yeah. Exactly. So shall we read one each? Yeah. We have reached major goals in the fields of cancer therapy and novel anti-infectives, two of the major causes of disease. Our future goal is to make the new therapies available to patients through suitable commercial partnerships. Reaching phase II, three studies, which is important, has been a long term goal and we have a strong pipeline of drug candidates in our portfolio to continue the translation of innovation into the clinic. Yes, and we have maintained strong momentum across both therapeutic areas with important advances. These achievements reflect the dedication of our teams that you can probably hear in the background here and provide a solid foundation for continued progress in the coming period. Thank you. The team who are here, they are not visible today due to the technology, but without this discovery platform and our extended network of experts, all these advances would not be possible. So we would like to thank everybody and all of you investors who are committed to supporting the company. I hope you're happy with us after this report. Thank you. Thank you. [Non-English content] [Non-English content] [Non-English content] [Non-English content] [Non-English content] [Non-English content] [Non-English content] [Non-English content] [Non-English content] [Non-English content] [Non-English content] [Non-English content] [Non-English content] [Non-English content] [Non-English content] [Non-English content] [Non-English content] [Non-English content] [Non-English content] [Non-English content] [Non-English content] [Non-English content] [Non-English content] [Non-English content] [Non-English content] [Non-English content]